Puluo Pharmaceutical: Majority-owned subsidiary obtains Cefradine Capsules "Drug Registration Certificate"

Puluo Pharmaceutical announced that its controlling subsidiary, Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., has received the Drug Administration's issued Cefdinir Capsule "Drug Registration Certificate", with a specification of 0.1g and registered classification as Class 4 chemical drugs. The drug has a wide range of indications, and the market size in the Chinese hospital market in 2024 is 380 million capsules, with sales amounting to 310 million yuan. As of the disclosure date of the announcement, the cumulative research and development investment in this drug is 5.2818 million yuan. The certification is considered equivalent to passing consistency evaluation, which is beneficial for expanding sales and improving competitiveness, but drug production and sales may be affected by factors such as policies and market conditions.